Open Access<p>Emerging Role of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis</p>
Author(s) -
Rhea Singh,
Courtney E Heron,
Rima I. Ghamrawi,
Lindsay C. Strowd,
Steven R. Feldman
Publication year - 2020
Publication title -
immunotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.256
H-Index - 7
ISSN - 2253-1556
DOI - 10.2147/itt.s229667
Subject(s) - janus kinase , medicine , atopic dermatitis , adverse effect , clinical trial , tofacitinib , immunology , dermatology , pharmacology , cytokine , rheumatoid arthritis
Atopic dermatitis (AD) is a common chronic, inflammatory skin condition. The pathogenesis of AD involves many cytokines that utilize the Janus kinase/signal transducer and activator of transcription (JAK-STAT) signaling cascade; therefore, JAK inhibitors may be used in the treatment of AD. This review aims to evaluate the pathophysiology, efficacy, and safety of JAK inhibitors and their emerging role as a therapeutic option for patients with AD.